Monopar Therapeutics Inc.
MNPR
$80.13
-$2.43-2.94%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.82M | 3.98M | 3.16M | 2.88M | 3.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.11M | 17.66M | 16.16M | 7.00M | 7.49M |
| Operating Income | -19.11M | -17.66M | -16.16M | -7.00M | -7.49M |
| Income Before Tax | -17.31M | -16.57M | -15.59M | -6.47M | -7.12M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.31 | -16.57 | -15.59 | -6.47 | -7.12 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.31M | -16.57M | -15.59M | -6.47M | -7.12M |
| EBIT | -19.11M | -17.66M | -16.16M | -7.00M | -7.49M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -3.33 | -3.46 | -3.60 | -1.99 | -2.31 |
| Normalized Basic EPS | -2.08 | -2.17 | -2.25 | -1.25 | -1.45 |
| EPS Diluted | -3.33 | -3.46 | -3.60 | -1.99 | -2.31 |
| Normalized Diluted EPS | -2.08 | -2.17 | -2.25 | -1.25 | -1.45 |
| Average Basic Shares Outstanding | 22.41M | 18.91M | 15.12M | 13.15M | 12.45M |
| Average Diluted Shares Outstanding | 22.41M | 18.91M | 15.12M | 13.15M | 12.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |